GlaxoSmithKline Tells Court It Aims to Seek Enhanced Damages in $235M Patent Case

, Delaware Business Court Insider

   | 0 Comments

GlaxoSmithKline told a Delaware federal judge on Monday that it will seek enhanced damages on a $235 million verdict against Teva Pharmaceutical for willfully infringing a patent for its hypertension drug Coreg.

This premium content is reserved for Delaware Business Court Insider subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202792770132

Thank you!

This article's comments will be reviewed.